Echosens has received US FDA approval for its FibroScan ® device and the company is planning to introduce this technology in the US market for the first time. Currently 1800 FibroScan devices are used worldwide in research and in everyday clinical use.

FibroScan  is used for clinical treatment of patients with liver disease such as chronic viral hepatitis C and B, and used with fatty liver disease. Based on a technology that is called transient elastography, measures of FibroScan the Scherwellengeschwindigkei the liver (in meters per second) and the corresponding stiffness (expressed in kilopascals) at 50 Hz in a fast, simple, non-invasive and completely painless way .

The FibroScan came on the market in Europe in 2003 and was the pioneer in the medical field for quantitative elastography. It was granted marketing approval in China (2008), Canada (2009), Brazil (2010) and Japan (2011) and is currently available in 70 countries.

FibroScan 660 to exist scientifically proven publications to make elastography device with the most evidence for clinical benefit. Moreover, the use of FibroScan is also mentioned in the guidelines and recommendations in different regions of the world like the World Health Organization, the European Association for the Study of the Liver (EASL), the Asian Pacific Association for the Study of liver disease meeting, etc.

FibroScan is of Echosens ( Paris made, France). Since its inception in 2001, Echosens has established itself as a leading provider of quantitative elastography. Echosens is specialized in research and development is very active and is the owner of 17 patent families, which are mainly in the area of the company's core technology: VCTE (TM) (Vibration Controlled Transient Elastography, vibration-controlled transient elastography).